A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild, Moderate, or Severe Hepatic Insufficiency
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2014
Price : $35 *
At a glance
- Drugs Valbenazine (Primary)
- Indications Drug-induced dyskinesia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Neurocrine Biosciences
- 14 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Oct 2013 Planned End Date changed from 1 Mar 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 09 Aug 2013 New trial record